Trial · NCT04074928
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses | QIVc | A/H1N1 | 78.0 | 95% Confidence Interval 70.75 to 86.03 | Titer |
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses | Comparator QIV | A/H1N1 | 57.3 | 95% Confidence Interval 50.76 to 64.63 | Titer |
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses | QIVc | B/Yamagata | 35.6 | 95% Confidence Interval 32.93 to 38.58 | Titer |
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses | Comparator QIV | B/Yamagata | 26.0 | 95% Confidence Interval 23.54 to 28.63 | Titer |
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses | QIVc | B/Victoria | 22.4 | 95% Confidence Interval 20.70 to 24.19 | Titer |
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses | Comparator QIV | B/Victoria | 19.6 | 95% Confidence Interval 17.81 to 21.58 | Titer |
| Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses | QIVc | A/H1N1 | 58.24 | 95% Confidence Interval 55.25 to 61.19 | Percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses | Comparator QIV | A/H1N1 | 46.78 | 95% Confidence Interval 42.64 to 50.96 | Percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses | QIVc | B/Yamagata | 46.52 | 95% Confidence Interval 43.53 to 49.53 | Percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses | Comparator QIV | B/Yamagata | 31.65 | 95% Confidence Interval 27.87 to 35.63 | Percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses | QIVc | B/Victoria | 30.31 | 95% Confidence Interval 27.60 to 33.13 | Percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses | Comparator QIV | B/Victoria | 24.35 | 95% Confidence Interval 20.89 to 28.07 | Percentage of participants |
| Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H3N2 Vaccine Strain by Microneutralization (MN) Assay Using Cell-derived Target Viruses | QIVc | 23.1 | 95% Confidence Interval 21.21 to 25.12 | Titer | |
| Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H3N2 Vaccine Strain by Microneutralization (MN) Assay Using Cell-derived Target Viruses | Comparator QIV | 23.9 | 95% Confidence Interval 21.57 to 26.57 | Titer | |
| Immunogenicity Endpoint: SCR and Difference in SCR Against the A/H3N2 Vaccine Strain by MN Assay Using Cell-derived Target Viruses | QIVc | 27.64 | 95% Confidence Interval 24.99 to 30.42 | Percentage of participants | |
| Immunogenicity Endpoint: SCR and Difference in SCR Against the A/H3N2 Vaccine Strain by MN Assay Using Cell-derived Target Viruses | Comparator QIV | 30.77 | 95% Confidence Interval 27.01 to 34.73 | Percentage of participants | |
| Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Egg-derived Target Viruses | QIVc | A/H1N1 Day 1 HAI GMT | 14.0 | 95% Confidence Interval 12.54 to 15.74 | Titer |
| Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Egg-derived Target Viruses | Comparator QIV | A/H1N1 Day 1 HAI GMT | 13.9 | 95% Confidence Interval 12.11 to 16.04 | Titer |
| Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Egg-derived Target Viruses | QIVc | A/H1N1 Day 29/57 HAI GMT | 92.2 | 95% Confidence Interval 83.62 to 101.71 | Titer |
| Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Egg-derived Target Viruses | Comparator QIV | A/H1N1 Day 29/57 HAI GMT | 82.9 | 95% Confidence Interval 73.51 to 93.58 | Titer |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04074928/results